Naveen Pemmaraju: Honored to work with and share our growing international collaboration with Gevorg Tamamyan and team in Armenia
Naveen Pemmaraju shared a post by Cancer Network on X/Twitter:
“Honored to work with and share our growing international collaboration with Gevorg Tamamyan and team in Armenia– Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in a Resource-Limited Setting.”
Quoting Cancer Network’s post:
“A great article focusing on BPDCN and treatment options for those working in a resource-limited setting.”
Source: Naveen Pemmaraju/X and Cancer Network/X
Naveen Pemmaraju is a Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center (MDACC) and Executive Director of MDACC Network. He is also the Leukemia Hematology/Oncology Course Director. His research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), MPN and AML. He has been named MDACC’s, Department of Leukemia, Inaugural Director of BPDCN Program, in 2020, which is one of the world’s most active BPDCN research programs. Dr. Pemmaraju is the recipient of the MDACC Gerald P. Bodey Award for Excellence in Education in 2020. He is a well-known social media influencer and advocate.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023